

## Australia's newest biotech incubator names first 16 innovative early-stage ventures taking up residency

19 April 2024 | News

**Aiming to build 'Australia's next CSL' by capitalising on the talent and capabilities**



Australia's newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility.

The state-of-the-art facilities, infrastructure, and support offered by Jumar creates a world-class hub for biotech innovation translation, research commercialisation, and talent development that will help to progress discoveries towards real-world patient treatments.

It aims to build "Australia's next CSL" by capitalising on the talent and capabilities of the local biotech research community to support the next homegrown global success story, and create a critical mass of entrepreneurial-skilled scientists who have the ability to run successful biotech companies.

The 16 innovative early-stage ventures include Tessara Therapeutics (creating "mini brains" in test tubes through 3D neural micro-tissues); Ovulation bio-sensing startup Symex Labs; Denteric (developing a therapeutic vaccine for the one billion people globally suffering from periodontal gum disease); Australian Genome Research Facility (agrf); Arovella Therapeutics (developing an invariant natural killer T (iNKT) cell therapy platform) licenced from Imperial College London to treat cancer); Centre for Biomedical Excellence (CBE); H3D's mission is to make custom-fit medical devices accessible for everyday people; Immunosis (developing a pioneering diagnostic platform, with the aim to promptly identify immune dysfunctions); Inosi Therapeutics (developing therapies to address fibrosis); Novoroo (develops new therapeutic approaches to address neurological damage); Nutromics' breakthrough technology involves a patch consisting of DNA-based sensors; Pacalis Therapeutics utilises intellectual property developed at Monash University to drive advancements in drug discovery; Qankorey are researching key technologies in prevention, screening, diagnosis and treatment of Alzheimer's disease; RAGE Biotech is developing novel therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE) for patients with difficult-to-treat inflammatory disease; Titan is a Contract Research Organisation (CRO); and 23Strands has developed a proven capability to deliver genome-wide DNA sequencing data.

.